A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Ixazomib (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Alliance
- 17 Jun 2022 Results assessing safety of the ixazomib-pomalidomide-dexamethasone (IXA-POM-DEX) combination for the treatment of pts with LEN and proteasome inhibitor (PI)-refractory MM presented at the 27th Congress of the European Haematology Association
- 01 Dec 2021 Results (n=29) published in the American Journal of Hematology
- 25 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Apr 2022.